Doxorubicin loaded silica nanorattles actively seek tumors with improved anti-tumor effects

Fuping Gao; Linlin Li; Tianlong Liu; Nanjing Hao; Huiyu Liu; Longfei Tan; Hongbo Li; Xinglu Huang; Bo Peng; Chuanmiao Yan; Liuqing Yang; Xiaoli Wu; Dong Chen; Fangqiong Tang

doi:10.1039/c2nr12094a

Doxorubicin loaded silica nanorattles actively seek tumors with improved anti-tumor effects

Fuping Gao, Linlin Li, Tianlong Liu, Nanjing Hao, Huiyu Liu, Longfei Tan, Hongbo Li, Xinglu Huang, Bo Peng, Chuanmiao Yan, Liuqing Yang, Xiaoli Wu, Dong Chen, Fangqiong Tang^*

^*Corresponding author for this work

CAS - Technical Institute of Physics and Chemistry

Research output: Contribution to journal › Article › peer-review

63 Citations (Scopus)

Abstract

Silica nanorattles (SNs) have proven to be promising vehicles for drug delivery. In order to further enhance efficacy and minimize adverse effects, active targeted delivery to tumors is necessary. In this work, SNs modified with a tumor specific targeting ligand, folic acid (FA), was used as carrier of doxorubicin (DOX) (DOX-FA-SNs). Drug loading, cytotoxicity and cellular uptake of DOX-FA-SNs in vitro in human cervical carcinoma cells (HeLa cells) were evaluated. DOX-FA-SNs showed a higher cytotoxicity in human cervical carcinoma cells (HeLa cells) than DOX loaded carboxyl (-COOH) and poly(ethylene glycol) (PEG) modified SNs (DOX-COOH-SNs and DOX-PEG-SNs, respectively). However, DOX-FA-SNs showed lower cytotoxicity in folate receptor negative normal mouse fibroblast cells (L929 cells) compared with free DOX. In vivo tumor-targeted fluorescence imaging indicated specific tumor targeting and uptake of FA-SNs in nude mice bearing subcutaneous HeLa cell-derived xenograft tumors. In vivo anti-tumor experiments demonstrated that DOX-FA-SNs (10 mg kg ^-1 of DOX) significantly regressed the tumor growth and reduced toxicity compared with free DOX. These results have great significance in developing and optimizing SNs as effective intracellular delivery and specific tumor targeting vehicles.

Original language	English
Pages (from-to)	3365-3372
Number of pages	8
Journal	Nanoscale
Volume	4
Issue number	11
DOIs	https://doi.org/10.1039/c2nr12094a
Publication status	Published - 7 Jun 2012
Externally published	Yes

Access to Document

10.1039/c2nr12094a

Cite this

@article{18d4d1c808784d16910139868d6ba196,

title = "Doxorubicin loaded silica nanorattles actively seek tumors with improved anti-tumor effects",

abstract = "Silica nanorattles (SNs) have proven to be promising vehicles for drug delivery. In order to further enhance efficacy and minimize adverse effects, active targeted delivery to tumors is necessary. In this work, SNs modified with a tumor specific targeting ligand, folic acid (FA), was used as carrier of doxorubicin (DOX) (DOX-FA-SNs). Drug loading, cytotoxicity and cellular uptake of DOX-FA-SNs in vitro in human cervical carcinoma cells (HeLa cells) were evaluated. DOX-FA-SNs showed a higher cytotoxicity in human cervical carcinoma cells (HeLa cells) than DOX loaded carboxyl (-COOH) and poly(ethylene glycol) (PEG) modified SNs (DOX-COOH-SNs and DOX-PEG-SNs, respectively). However, DOX-FA-SNs showed lower cytotoxicity in folate receptor negative normal mouse fibroblast cells (L929 cells) compared with free DOX. In vivo tumor-targeted fluorescence imaging indicated specific tumor targeting and uptake of FA-SNs in nude mice bearing subcutaneous HeLa cell-derived xenograft tumors. In vivo anti-tumor experiments demonstrated that DOX-FA-SNs (10 mg kg -1 of DOX) significantly regressed the tumor growth and reduced toxicity compared with free DOX. These results have great significance in developing and optimizing SNs as effective intracellular delivery and specific tumor targeting vehicles.",

author = "Fuping Gao and Linlin Li and Tianlong Liu and Nanjing Hao and Huiyu Liu and Longfei Tan and Hongbo Li and Xinglu Huang and Bo Peng and Chuanmiao Yan and Liuqing Yang and Xiaoli Wu and Dong Chen and Fangqiong Tang",

year = "2012",

month = jun,

day = "7",

doi = "10.1039/c2nr12094a",

language = "English",

volume = "4",

pages = "3365--3372",

journal = "Nanoscale",

issn = "2040-3364",

publisher = "Royal Society of Chemistry",

number = "11",

}

TY - JOUR

T1 - Doxorubicin loaded silica nanorattles actively seek tumors with improved anti-tumor effects

AU - Gao, Fuping

AU - Li, Linlin

AU - Liu, Tianlong

AU - Hao, Nanjing

AU - Liu, Huiyu

AU - Tan, Longfei

AU - Li, Hongbo

AU - Huang, Xinglu

AU - Peng, Bo

AU - Yan, Chuanmiao

AU - Yang, Liuqing

AU - Wu, Xiaoli

AU - Chen, Dong

AU - Tang, Fangqiong

PY - 2012/6/7

Y1 - 2012/6/7

N2 - Silica nanorattles (SNs) have proven to be promising vehicles for drug delivery. In order to further enhance efficacy and minimize adverse effects, active targeted delivery to tumors is necessary. In this work, SNs modified with a tumor specific targeting ligand, folic acid (FA), was used as carrier of doxorubicin (DOX) (DOX-FA-SNs). Drug loading, cytotoxicity and cellular uptake of DOX-FA-SNs in vitro in human cervical carcinoma cells (HeLa cells) were evaluated. DOX-FA-SNs showed a higher cytotoxicity in human cervical carcinoma cells (HeLa cells) than DOX loaded carboxyl (-COOH) and poly(ethylene glycol) (PEG) modified SNs (DOX-COOH-SNs and DOX-PEG-SNs, respectively). However, DOX-FA-SNs showed lower cytotoxicity in folate receptor negative normal mouse fibroblast cells (L929 cells) compared with free DOX. In vivo tumor-targeted fluorescence imaging indicated specific tumor targeting and uptake of FA-SNs in nude mice bearing subcutaneous HeLa cell-derived xenograft tumors. In vivo anti-tumor experiments demonstrated that DOX-FA-SNs (10 mg kg -1 of DOX) significantly regressed the tumor growth and reduced toxicity compared with free DOX. These results have great significance in developing and optimizing SNs as effective intracellular delivery and specific tumor targeting vehicles.

AB - Silica nanorattles (SNs) have proven to be promising vehicles for drug delivery. In order to further enhance efficacy and minimize adverse effects, active targeted delivery to tumors is necessary. In this work, SNs modified with a tumor specific targeting ligand, folic acid (FA), was used as carrier of doxorubicin (DOX) (DOX-FA-SNs). Drug loading, cytotoxicity and cellular uptake of DOX-FA-SNs in vitro in human cervical carcinoma cells (HeLa cells) were evaluated. DOX-FA-SNs showed a higher cytotoxicity in human cervical carcinoma cells (HeLa cells) than DOX loaded carboxyl (-COOH) and poly(ethylene glycol) (PEG) modified SNs (DOX-COOH-SNs and DOX-PEG-SNs, respectively). However, DOX-FA-SNs showed lower cytotoxicity in folate receptor negative normal mouse fibroblast cells (L929 cells) compared with free DOX. In vivo tumor-targeted fluorescence imaging indicated specific tumor targeting and uptake of FA-SNs in nude mice bearing subcutaneous HeLa cell-derived xenograft tumors. In vivo anti-tumor experiments demonstrated that DOX-FA-SNs (10 mg kg -1 of DOX) significantly regressed the tumor growth and reduced toxicity compared with free DOX. These results have great significance in developing and optimizing SNs as effective intracellular delivery and specific tumor targeting vehicles.

UR - http://www.scopus.com/inward/record.url?scp=84861370981&partnerID=8YFLogxK

U2 - 10.1039/c2nr12094a

DO - 10.1039/c2nr12094a

M3 - Article

C2 - 22538830

AN - SCOPUS:84861370981

SN - 2040-3364

VL - 4

SP - 3365

EP - 3372

JO - Nanoscale

JF - Nanoscale

IS - 11

ER -

Doxorubicin loaded silica nanorattles actively seek tumors with improved anti-tumor effects

Abstract

Access to Document

Other files and links

Fingerprint

Cite this